Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic lymphocytic leukemia (CLL) meeting the following criteria:~  * Minimum threshold peripheral lymphocyte count of 5 x 10\^9/L (CLL variant) OR palpable adenopathy \> 1 cm or palpable splenomegaly 9small lymphocytic lymphoma \[SLL\] variant)~ * Immunophenotypic demonstrations of a population of B-lymphocytes (as defined by CD19+) that are monoclonal (by light-chain exclusion) AND have ≥ 3 of the following characteristics:~    * CD5+~   * CD23+~   * Dim surface light chain expression~   * Dim surface CD20 expression~ * FISH analysis is negative for immunoglobulin heavy chain/cyclin D1 gene (IGH/CCND1) and/or immunostaining is negative for cyclin D1 expression (to exclude mantle cell lymphoma)~* Progressive, symptomatic CLL, defined by at least one of the following:~  * Weight loss \> 10% within the past 6 months attributable to progressive CLL (grade 2 or higher)~ * Extreme fatigue attributable to progressive CLL (grade 3 or higher)~ * Fevers \> 100.5° F for 2 weeks without evidence of infection (grade 1 or higher)~ * Night sweats without evidence of infection (drenching)~ * Evidence of progressive bone marrow failure with hemoglobin \< 11 g/dL or platelet count \< 100 x 10\^9/L~ * Rapidly progressive lymphadenopathy for which the largest node is ≤ 5 cm in any dimension~    * Largest lymph nodes involved in the neck, axilla, and groin need to be measured and followed for response~Exclusion Criteria:~* Prior treatment for CLL~* Massive splenomegaly \> 6 cm below left costal margin, at rest, on clinical examination~* Lymphadenopathy \> 5 cm in any diameter~* New York Heart Association class III or IV heart disease~* Recent myocardial infarction (within the past month)~* Uncontrolled infection~* Infection with the human immunodeficiency virus (HIV/AIDS)~* Serological evidence of active hepatitis B infection (HBsAg or HBeAg positive)~* Positive hepatitis C serology~* Evidence of active autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia~* Other active primary malignancy requiring treatment or that limits survival to ≤ 2 years, except for in situ carcinoma of the cervix or breast or non-metastatic basal cell or squamous cell carcinoma of the skin~* Major surgery within 4 weeks prior to pre-registration~* Concomitant use of continuous systemic corticosteroids~  * Prior corticosteroids are allowed but not at time of pre-registration to the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (standard dose) (Type: ACTIVE_COMPARATOR): Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m\^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week.
- Arm B (low dose) (Type: EXPERIMENTAL): Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m\^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).